Email updates

Keep up to date with the latest news and content from Molecular Cancer and BioMed Central.

Open Access Research

The haematopoietic GTPase RhoH modulates IL3 signalling through regulation of STAT activity and IL3 receptor expression

Mehtap S Gündogdu1, He Liu23, Daniela Metzdorf1, Dagmar Hildebrand1, Michael Aigner4, Klaus Aktories2, Klaus Heeg1 and Katharina F Kubatzky1*

Author Affiliations

1 Department für Infektiologie, Medizinische Mikrobiologie und Hygiene, Ruprecht-Karls-Universität, Im Neuenheimer Feld 324, D-69120 Heidelberg, Germany

2 Institut für Experimentelle und Klinische Pharmakologie and Toxikologie, Albert-Ludwigs-Universität, Albertstraße 25, D-79104 Freiburg, Germany

3 Department of Pharmacology, University of Bern, Friedbühlstr. 49, CH-3010 Bern, Switzerland

4 Medizinische Klinik 5, Hämatologie und Internistische Onkologie, Universitätsklinikum Erlangen, Glückstr. 4a, D-91054 Erlangen, Germany

For all author emails, please log on.

Molecular Cancer 2010, 9:225  doi:10.1186/1476-4598-9-225

Published: 25 August 2010

Abstract

Background

RhoH is a constitutively active member of the family of Rho GTPases. Its expression is restricted to the haematopoietic lineage, where it serves as a positive regulator for T cell selection and mast cell function and as a negative regulator for growth-related functions in other lineages. Here, we examined the activation of signal transducer and activator of transcription (STAT) proteins in response to stimulation with interleukin 3 (IL3).

Results

Using the murine IL3-dependent cell line BaF3 we investigated the influence of RhoH protein expression levels on IL3-mediated cellular responses. RhoH overexpressing cells showed lower sensitivity to IL3 and decreased STAT5 activation. SiRNA-mediated repression of RhoH gene expression led to an increase in proliferation and STAT5 activity which correlated with an increased number of IL3 receptor α chain molecules, also known as CD123, expressed at the cell surface. Interestingly, these findings could be reproduced using human THP-1 cells as a model system for acute myeloid leukaemia, where low RhoH levels are known to be an unfavourable prognostic marker. Overexpression of RhoH on the other hand caused an induction of STAT1 activity and western blot analysis revealed that activated STAT1 is phosphorylated on Tyr701. STAT1 is known to induce apoptosis or cell cycle arrest and we detected an upregulation of cyclin-dependent kinase inhibitors (CDKI) p21Cip1 and p27Kip1 in RhoH overexpressing BaF3 cells.

Conclusions

We propose that RhoH functions as a negative regulator for IL3-induced signals through modulation of the JAK-STAT pathway. High levels of RhoH allow the IL3-dependent activation of STAT1 causing decreased proliferation through upregulation of p21Cip1 and p27Kip1. Low RhoH levels on the other hand led to an upregulation of IL3-dependent cell growth, STAT5 activity and an increase of CD123 surface expression, linking RhoH to a CD123/STAT5 phenotype that has been described in AML patients.